About

Mehul Desai, PharmD, MBA, serves as Vice-President of Medical Affairs at Enable Injections. His experience includes development and execution of tactical plans, driving strategic direction through key opinion leader insights, supporting clinical trial execution and contributing to business development activities across various therapeutic areas.

His background includes being the Associate Medical Director for the haematology franchise at argenx. Prior to this, his experience included field medical assignments in rare disease for haematology at argenx, haematology/nephrology at Alexion, and nephrology/neurology at Mallinckrodt Pharmaceuticals.

Dr Desai holds a Bachelor’s degree in Biochemistry and Business Foundations from Indiana University (Bloomington, IN, US); a PharmD from Purdue University (West Lafayette, IN, US); and an MBA in Pharmaceutical and Healthcare Business from the University of the Sciences (Philadelphia, PA, US).

Contributions

WEARABLES

A NEW FRONTIER: SELF-ADMINISTRATION OF LYOPHILISED, LARGE-VOLUME SUBCUTANEOUS BIOLOGICS

Mehul Desai and Daniel Waites discuss the pros and cons of lyophilisation for biologic injectable drugs, and how Enable Injections’ enFuse device can provide an answer to the challenges of self-injection of large-volume and lyophilised biologics.

More contributions

WEARABLES

REDUCE PHARMA DEVELOPMENT TIME: LARGE-VOLUME SUBCUTANEOUS DELIVERY WITH THE ENFUSE^®

Mehul Desai discusses how Enable Injections' enFuse^® delivery system provides a flexible alternative for subcutaneous administration of high-volume therapeutics.

WEARABLES

FLEXIBLE CARE – ENABLE WEARABLE DELIVERY

Jennifer Estep and Mehul Desai discuss the benefits for patients and healthcare providers of innovative subcutaneous delivery.